Peer Review, UGC Care
Owner: SEOBADBOYZ

https://ejournalfpikunipa.ac.id/

https://pengabdian.otusedujournal.ac.id/

https://jim.ar-raniry.ac.id/

https://ejurnal.unisan.ac.id/index.php/electrichsan

https://journal.ar-raniry.ac.id/index.php/fitrah

https://jurnal.stainwsamawa.ac.id/index.php/al-bayan

https://ojs.palcomtech.ac.id/index.php/teknomatika

https://journal.man1yogyakarta.sch.id/ulilalbab/editorialTeam

https://icess.uin-suska.ac.id/index.php/cijpm

https://jpbm.uho.ac.id/index.php/journal/search

https://psychospiritual.uinkhas.ac.id/index.php/psycho/EditorialTeam

https://sij.unsa.ac.id/

Owner: SEOBADBOYZ

https://jubdimas.itscience.org/index.php/jubdimas

https://jintegrativederm.org/doi/10.64550/joid.xph19q87

https://ujmcs.tstu.uz/index.php/ujmcs/ujmcs

https://www.alfleth.com/

https://journalkeberlanjutan.com/index.php/JoGTA/index

https://revistas.pucp.edu.pe/index.php/derechopucp

Owner: SEOBADBOYZ

TIP4D

TIP4D

TIP4D

TIP4D

TIP4D

TIP4D

TIP4D

TIP4D

SHIOWLA

TIP4D

TIP4D

TIP4D

TIP4D

TIP4D

TIP4D

TIP4D

TIP4D

SLOT DEMO

CRYSTALLOGRAPHIC CHARACTERIZATION OF TRANS ESTERIFIED POTENTIAL IMPURITY OF CANDESARTAN
View PDF

Keywords

Candesartan - Impurity - Single Crystal - Intermolecular N - alkylation.

How to Cite

Renalson, K. S., Kalambe, A. B. ., Panhekar, D. Y. ., & Bandichhor, R. . (2015). CRYSTALLOGRAPHIC CHARACTERIZATION OF TRANS ESTERIFIED POTENTIAL IMPURITY OF CANDESARTAN. International Journal of Research and Development in Pharmacy & Life Sciences, 4(2), 1073-1076. Retrieved from https://ijrdpl.com/index.php/ijrdpl/article/view/416

Abstract

The title compound (CDC II), C28H28N6O3, is a potential impurity found in commercial product candesartan cilexetil, consist of N- ethylation of tetrazole moiety attached to biphenyl ring, selectively at N-6 position. The Crystal structure held together by C-H×××O intermolecular interactions. Crystal structure of the title compound was obtained by single crystal X-ray diffraction which was crystallizes in the monoclinic space group P21/n with cell parameter a = 12.1574(12)Å, b = 13.9178(14)Å,c = 15.9742(19)Å and Z = 4.

View PDF

References

World Health Organization, 1211 Geneva 27, Switzerland, www.who.int/en

S. Ahuja, Impurities evaluation in pharmaceuticals, Marcel Deckker, NY, 1998

ICH guideline, Impurities in new drug substances Q3A (R1) dated 7 February 2002

U.S. Department of Health and Human Services Food and Drug Administration, Guidance for Industry, ANDAs: Impurities in Drug Substances, January 2005.

Committee for proprietary medicinal products, Guideline on control of impurities in pharmaceutical substance, Apr 2004.

Raman B, Sharma B , Mahale G, Singh D, Kumar A (2011) Journal of Pharmaceutical and Biomedical Analysis 56:256-263

S.C. Sweetman (Ed.), Martindale – The Complete Drug Reference, 36th ed., Pharmaceutical Press, London, 2009, 1238–1239

Etinger MY, Hildesheim VN, Fedotev B, Dolitzky B, WO Patent 2005//111021 A1.

H. Stenhoff, P. Lagerstrom, C. Andersen, (1999) Journal of Chromatography B 731: 411–417

N. Ferreiros, S. Dresen, R.M. Alonso, W. Weinmann, J. Chromatography B 855 (2007) 134–13

J. Havlicek, Z. Mandelova, R. Weisemann , I. Strelec, L. Placek, S. Radl , Collct. Czech. Chem. Commun. 74 (2009) 347–362.

Oxford Diffraction (2009). CrysAlis CCD and CrysAlisPro RED, Version 1.171.33.34d. Oxford Diffraction Ltd., Abingdon, Oxfordshire, England

Sheldrick, G. M. (2008) Acta Cryst. A64, 112-122

Spek, A. L. (2003) J. Appl. Crystallogr. 36, 7-13

Farrugia, L. J. (1999) J. Appl. Cryst. 32, 837-8

Creative Commons License

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

Copyright (c) 2020 Array

Downloads

Download data is not yet available.